Optimizing Treatment for Rare Chronic Autoimmune Disease Myasthenia Gravis

Rare diseases and orphan drugs continue to be at the forefront of novel development and groundbreaking research. Almost 30 orphan medications were approved by the FDA during 2021.

One treatment, which received FDA approval on December 17, 2021, Vyvgart, is a treatment for myasthenia gravis, a rare and chronic neuromuscular disease where abnormal circulating AChR autoantibodies wrongly attack healthy tissues. This drug requires administration by intravenous infusion once weekly for four weeks. Additional treatment cycles are based on clinical evaluation.

Vyvgart is expected to see much broader use in the future across a spectrum of IgG-mediated diseases. Clinical trials are currently underway evaluating Vyvgart in five other rare disorders, including primary immune thrombocytopenia and pemphigus.

AscellaHealth’s end-to-end Specialty Pharmacy solutions enhance provider and patient education, improve patient access and increase biosimilar utilization.

To learn more about the potential cost-saving opportunities of biosimilars and interchangeable biosimilar products, click here.